ABSTRACT 

Maintaining primary teeth in the oral cavity until the time of physiological exfoliation is important for mastication, speech, esthetics, preservation of arch integrity, and guidance of permanent tooth eruption. Preserving pulp vitality in the treatment of deep dentinal caries has become one of the fundamental goals of modern pediatric dentistry. In the past, materials such as formocresol, ferric sulfate, and calcium hydroxide were used in pulpotomy techniques; however, advances in pulp biology and the development of bioactive materials have shifted treatment strategies from fixation or devitalization toward pulp preservation and support of biological healing. In this evolution, the high biocompatibility, sealing ability, capacity to create an alkaline environment, and ability to support mineralized tissue formation of mineral trioxide aggregate (MTA) have played an important role. Nevertheless, disadvantages of some MTA formulations, including long setting time, difficult handling, high cost, and discoloration, have led to the development of new calcium silicate-based materials. Biodentine, NeoMTA Plus, NeoMTA 2, and NeoPutty were developed to improve handling characteristics, physical properties, and color stability. Current clinical studies, systematic reviews, and meta-analyses report that MTA and Biodentine show high and generally comparable clinical and radiographic success rates in primary-tooth pulpotomy. Although new-generation premixed materials also show promising short- and medium-term results, their long-term clinical evidence is not as extensive as that for MTA and Biodentine. The aim of this review is to evaluate the biological properties, clinical applications, advantages, disadvantages, and current clinical evidence for calcium silicate-based bioceramic materials used in vital pulp therapy of primary teeth [1-4].
 

KEYWORDS

Primary teeth, vital pulp therapy, pulpotomy, mineral trioxide aggregate, Biodentine, bioceramic, calcium silicate.
 

REFERENCES

1) Coll JA, Dhar V, Chen CY, Crystal YO, Guelmann M, Marghalani AA, et al. Use of vital pulp therapies in primary teeth 2024. Pediatr Dent. 2024;46(1):13-26.
2) Dhar V, El-Karim I, Coll JA, Fouad AF, O’Connell AC, Asgary S, et al. Consensus-based recommendations on pulp therapies in primary and permanent teeth: IAPD Porto Forum. Int J Paediatr Dent. 2026;36(2):371-386. doi:10.1111/ipd.70068.
3) Parisay I, Ghoddusi J, Forghani M. A review on vital pulp therapy in primary teeth. Iran Endod J. 2015;10(1):6-15.
4) Coll JA, Seale NS, Vargas K, Marghalani AA, Al Shamali S, Graham L. Primary tooth vital pulp therapy: a systematic review and meta-analysis. Pediatr Dent. 2017;39(1):16-123.
5) Parirokh M, Torabinejad M. Mineral trioxide aggregate: a comprehensive literature review—Part I: chemical, physical, and antibacterial properties. J Endod. 2010;36(1):16-27. doi:10.1016/j.joen.2009.09.006.
6) Torabinejad M, Parirokh M. Mineral trioxide aggregate: a comprehensive literature review—Part II: leakage and biocompatibility investigations. J Endod. 2010;36(2):190-202. doi:10.1016/j.joen.2009.09.010.
7) Parirokh M, Torabinejad M. Mineral trioxide aggregate: a comprehensive literature review—Part III: clinical applications, drawbacks, and mechanism of action. J Endod. 2010;36(3):400-413. doi:10.1016/j.joen.2009.09.009.
8) Rajasekharan S, Martens LC, Cauwels RGEC, Verbeeck RMH. Biodentine material characteristics and clinical applications: a review of the literature. Eur Arch Paediatr Dent. 2014;15(3):147-158. doi:10.1007/s40368-014-0114-3.
9) Rajasekharan S, Martens LC, Cauwels RGEC, Anthonappa RP. Biodentine material characteristics and clinical applications: a 3 year literature review and update. Eur Arch Paediatr Dent. 2018;19(1):1-22. doi:10.1007/s40368-018-0328-x.
10) Malkondu Ö, Karapinar Kazandağ M, Kazazoğlu E. A review on Biodentine, a contemporary dentine replacement and repair material. Biomed Res Int. 2014;2014:160951. doi:10.1155/2014/160951.
11) Holan G, Eidelman E, Fuks AB. Long-term evaluation of pulpotomy in primary molars using mineral trioxide aggregate or formocresol. Pediatr Dent. 2005;27(2):129-136.
12) Farsi N, Alamoudi N, Balto K, Mushayt A. Success of mineral trioxide aggregate in pulpotomized primary molars. J Clin Pediatr Dent. 2005;29(4):307-311. doi:10.17796/jcpd.29.4.n80t77w625118k73.
13) Cuadros-Fernández C, Lorente Rodríguez AI, Sáez-Martínez S, García-Binimelis J, About I, Mercadé M. Short-term treatment outcome of pulpotomies in primary molars using mineral trioxide aggregate and Biodentine: a randomized clinical trial. Clin Oral Investig. 2016;20(7):1639-1645. doi:10.1007/s00784-015-1656-4.
14) Bani M, Aktaş N, Çınar Ç, Odabaş ME. The clinical and radiographic success of primary molar pulpotomy using Biodentine and mineral trioxide aggregate: a 24-month randomized clinical trial. Pediatr Dent. 2017;39(4):284-288.
15) Guven Y, Aksakal SD, Avcu N, Unsal G, Tuna EB, Aktoren O. Success rates of pulpotomies in primary molars using calcium silicate-based materials: a randomized control trial. Biomed Res Int. 2017;2017:4059703. doi:10.1155/2017/4059703.
16) Nagendrababu V, Pulikkotil SJ, Veettil SK, Jinatongthai P, Gutmann JL. Efficacy of Biodentine and mineral trioxide aggregate in primary molar pulpotomies—a systematic review and meta-analysis with trial sequential analysis of randomized clinical trials. J Evid Based Dent Pract. 2019;19(1):17-27. doi:10.1016/j.jebdp.2018.05.002.
17) Stringhini Junior E, Dos Santos MGC, Oliveira LB, Mercadé M. MTA and Biodentine for primary teeth pulpotomy: a systematic review and meta-analysis of clinical trials. Clin Oral Investig. 2019;23(4):1967-1976. doi:10.1007/s00784-018-2616-6.
18) Vilella-Pastor S, Sáez S, Veloso A, Guinot-Jimeno F, Mercadé M. Long-term evaluation of primary teeth molar pulpotomies with Biodentine and MTA: a CONSORT randomized clinical trial. Eur Arch Paediatr Dent. 2021;22(4):685-692. doi:10.1007/s40368-021-00616-3.
19) Guo J, Zhang N, Cheng Y. Comparative efficacy of medicaments or techniques for pulpotomy of primary molars: a network meta-analysis. Clin Oral Investig. 2023;27(1):91-104. doi:10.1007/s00784-022-04830-1.
20) Alqahtani AS, Alsuhaibani NN, Sulimany AM, Bawazir OA. NeoPUTTY versus NeoMTA 2 as a pulpotomy medicament for primary molars: a randomized clinical trial. Pediatr Dent. 2023;45(3):240-244.
21) Abdelwahab DH, Kabil NS, Badran AS, Darwish D, Abd El Geleel OM. One-year radiographic and clinical performance of bioactive materials in primary molar pulpotomy: a randomized controlled trial. J Dent. 2024;143:104864. doi:10.1016/j.jdent.2024.104864.
22) Tungjitphianpong P, Trairatvorakul C, Thunyakitpisal P, Songsiripradubboon S. Partial pulpotomy success in primary molars followed up for 24 months: a randomized controlled clinical trial using mineral trioxide aggregate, Biodentine, and acemannan. Int J Paediatr Dent. 2024;34(5):630-638. doi:10.1111/ipd.13163.
23) Talekar AL, Musale PK, Chaudhari GS, Silotry TMH, Waggoner WF. A prospective randomised clinical trial evaluating pulpotomy in primary molars with three bioceramic calcium silicate cements: 24 month follow-up. Int J Paediatr Dent. 2025;35(4):763-773. doi:10.1111/ipd.13288.
24) Lu KYF, Gibbs JL, Wu CY, Blatz MB, Ma X, Fu MW, et al. Efficacy of Biodentine versus mineral trioxide aggregate in pulpotomy for primary teeth: a systematic review and meta-analysis of randomized controlled trials. J Evid Based Dent Pract. 2025;25(4):102191. doi:10.1016/j.jebdp.2025.102191.
25) Ardila CM, Vivares-Builes AM, Pineda-Vélez E. Clinical and radiographic outcomes of calcium-silicate-based materials in primary-tooth pulpotomy: an umbrella review. J Clin Med. 2026;15(16):6379. doi:10.3390/jcm15166379.

Cite this article

ALMAK, Z. (2026). Bioceramic Materıals in Vital Pulp Therapy of Prımary Teeth: A Contemporary Approach from Mta to New-Generatıon Calcıum Silicate-Based Materials. INTERNATIONAL JOURNAL OF HEALTH & MEDICAL RESEARCH, 5(11), 1149-1156. https://doi.org/10.58806/ijhmr.2026.v5i11n04